Search results
Results From The WOW.Com Content Network
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
Having a user account with a large number of edits implies that the user is knowledgeable, experienced, knows what they are doing, is familiar with Wikipedia policies and procedures, has a handle on most of Wikipedia's acronyms and abbreviations, understands the difference between things like a template and a tag, a meatpuppet and a sockpuppet ...
Editis was created in January 2004 by the regrouping of approximately 60% of the publishing assets of Vivendi, the other part remaining with Lagardère Group. [5]Editis was, for 4 years (until May 2008), part of Wendel, a financial investment group which had acquired it from Investima10 (a financial ad hoc structure holding Vivendi Universal Publishing assets after Lagardère's purchase in 2003).
He is the executive chairman at genome editing company Editas Medicine since 2018, where he was CEO between 2021 and 2022. [1] [2] [3] He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. [4] At the same time, he started he would retire from the board at the end of his term. [5]
Edita (E-dee-ta) is a Slavic female first name, a form of Edith.It may refer to: Edita Abdieski (born 1984), Swiss singer; Edita Adlerová (born 1971), Czech opera singer; Edita Aradinović (born 1993), Serbian singer
Editas announced in 2019 that it had found early success in research on EDIT-301, an experimental cell medicine, as a potential treatment for sickle cell disease and beta-thalassemia. [18] [19] In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body . As part of the clinical ...
Intellia Therapeutics was founded in November 2014 to develop biopharmaceuticals using CRISPR. [7] [8]It was backed by Atlas Venture and Novartis; the founding CEO was Nessan Bermingham from Atlas and the founding CSO was John Leonard, formerly CSO of AbbVie.
Juno Therapeutics Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.